DSGN - Design Therapeutics, Inc. News

Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of D

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatmen

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial

GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and

seekingalpha.com

Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts

Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to ta

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clini

TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvement

Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May

Dow falls over 100 points, NASDAQ down 1.20% and S&P 500 down 0.64%. Energy shares surge, tech s

Nasdaq Down 200 Points; Brady Earnings Top Views

US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares

seekingalpha.com

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ata

Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Tria

Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatment

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endo

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Fr

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clini

Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock

Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares de

zacks.com

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investo

Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monda

U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also

Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21

Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperfor

12 Health Care Stocks Moving In Thursday's Intraday Session

seekingalpha.com

Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript

12 Health Care Stocks Moving In Wednesday's Intraday Session

Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.29) per share which beat the anal

Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapir

Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15

Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a

RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14

RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform

Design Therapeutics Q4 EPS $(0.27) Beats $(0.35) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.27) per share which beat the anal

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00

Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recomm

Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin

Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why

Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on F

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00

Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of

Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target

Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a

Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why

Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report)'s stock price traded down 4.5% during mid

Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market P

Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin

Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving

RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13

RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perfor

247wallst.com

Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, J

The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter re

RBC Capital Maintains Sector Perform on Design Therapeutics, Raises Price Target to $6

RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Sector Per

Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.30) per share which beat the anal

Design Therapeutics Gets Clearance To Start Dosing DM1 Participants In Phase 1 Multiple-Ascending Do

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatmen

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic

Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller

Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two

Design Therapeutics Q2 EPS $(0.34) Misses $(0.33) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.34) per share which missed the an

Design Therapeutics Submitted An Investigational New Drug Application For DT-216P2 With The FDA, The

Further details will be provided in an official letter from FDA within 30 days and the company plans

Design Therapeutics Announced That The First Friedreich Ataxia Patient Has Been Dosed Via Intravenou

The RESTORE-FA trial is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and ph

Design Therapeutics Q1 EPS $(0.31) Misses $(0.28) Estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.31) per share which missed the an

'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines

Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker T

esign Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments

Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clin